The Influence of Hepatitis C Virus Coinfection on the Risk of Lipid Abnormalities in a Cohort of HIV-1-Infected Patients after Initiation of Highly Active Antiretroviral Therapy [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 1, 2004, Pages 641-642

  Di Giambenedetto, Simona ^a   Baldini, Francesco ^b   Cingolani, Antonella ^a   Tamburrini, Enrica ^a   Cauda, Roberto ^a   De Luca, Andrea ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ANTIVIRAL ACTIVITY; BODY FAT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; MALE; RISK FACTORS;

EID: 2142714478     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200405010-00015     Document Type: Letter

References (8)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 20;349:2065-2067.
3. Carr A, Samaras K, Chisholm D, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;352: 1881-1883.
4. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 27:245-250.
5. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17: 1179-1193.
6. Collazos J, Mayo J, Ibarra S, et al. Hyperlipidaemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS. 2003;17:927-929.
7. Torti C, Patroni A, Tinelli C, et al. Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:315-316.
8. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.